Gilles Lugassy - Concepedia

Author

Gilles Lugassy

Barzilai Medical Center

Also Known As

G Lugassy, G. LUGASSY, G. Lugassy, Gilles Lugassy, Lugassy Gilles

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Barzilai Medical Center Ben-Gurion University of the Negev Hadassah Medical Center Hadassah Academic College Kaplan Medical Center

About

Gilles Lugassy is an author at Barzilai Medical Center specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	555
2	Health Sciences	8	8	354
3	Allergy	2	2	24
4	Cell Biology	2	2	160
5	Arts	1	1	41

Gilles Lugassy

Publications

892

Citations

H-Index

Page 1

	Year	Citations
Novel role of 1,25(OH)2D3 in induction of erythroid progenitor cell proliferation Dora Ben Alon, Cidio Chaimovitz, Alexander Dvilansky, Experimental Hematology Developmental BiologyCell RegulationCell DivisionMedicineNovel Role	2002	124
The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. M Schlesinger, I Broman, Gilles Lugassy PubMed	1996	76
Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy Arthur Machlenkin, Adrian Paz, Erez Bar Haim, Cancer Research	2005	75
Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma Abraham Klepfish, Gilles Lugassy, Kotsianidis Ioannis, Annals of the New York Academy of Sciences Hematological MalignancyRtx 375Complement SystemLymphoid NeoplasiaChronic Lymphocytic Leukemia	2009	57
Conventional Dose Fludarabine-based Regimens are Effective but have Excessive Toxicity in Elderly Patients with Refractory Chronic Lymphocytic Leukemia Lev Shvidel, Mordechai Shtalrid, Osnat Bairey, Leukemia & lymphoma/Leukemia and lymphoma	2003	52
Autoimmunity and auto-immune syndromes associated with and preceding the development of lymphoproliferative disorders. Aaron Polliack, Gilles Lugassy PubMed	1992	47
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, The Lancet Haematology Hematological MalignancyOncologyTransplantationHematologyClinical Trials	2022	44
Sensorineural hearing loss associated with vincristine treatment Gilles Lugassy, Amnon Shapira Annals of Hematology Sensorineural Hearing LossAudiologyAuditory ResearchCochlear ImplantAuditory Science	1990	41
Major airway obstruction relieved by helium/oxygen breathing Solly Mizrahi, Yosef Yaʼari, Gilles Lugassy, Critical Care Medicine Critical Care MedicineClinical Case ReportG. MdPulmonary PhysiologyCase Series	1986	39
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study Pieter W. Kamphuisen, A.Y.Y. Lee, Guy Meyer, Journal of Thrombosis and Haemostasis ThrombosisPulmonary EmbolismVenous ThrombosisVenous Disease TreatmentRelevant Bleeding	2018	37

Page 1